Black Rock Inc. Zynerba Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.3 - $0.43 $29,453 - $42,216	-98,178 Reduced 11.71%	740,524 $244,000
Q1 2023 May 12, 2023	BUY	$0.4 - $0.67 $1,032 - $1,729	2,582 Added 0.31%	838,702 $360,000
Q4 2022 Feb 13, 2023	BUY	$0.5 - $0.72 $684 - $984	1,368 Added 0.16%	836,120 $443,000
Q3 2022 Nov 14, 2022	SELL	$0.87 - $1.36 $7,769 - $12,146	-8,931 Reduced 1.06%	834,752 $611,000
Q2 2022 Aug 12, 2022	BUY	$0.86 - $2.06 $4,492 - $10,761	5,224 Added 0.62%	843,683 $962,000
Q1 2022 May 12, 2022	BUY	$1.83 - $3.02 $5,144 - $8,489	2,811 Added 0.34%	838,459 $1.72 Million
Q4 2021 Feb 10, 2022	SELL	$2.88 - $4.3 $15,854 - $23,671	-5,505 Reduced 0.65%	835,648 $2.41 Million
Q3 2021 Nov 09, 2021	BUY	$3.72 - $5.35 $248,827 - $357,856	66,889 Added 8.64%	841,153 $3.57 Million
Q2 2021 Aug 11, 2021	BUY	$3.83 - $5.98 $2.97 Million - $4.63 Million	774,264 New	774,264 $4.1 Million

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.